Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Sep 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.99%9.55B | 12.63%2.43B | 18.46%2.39B | 30.18%8.76B | 36.65%2.4B | 26.76%2.18B | 27.80%2.16B | 29.26%2.02B | 17.00%6.73B | 17.94%1.76B |
Cost of revenue | 10.59%7.38B | 15.77%1.85B | 17.24%1.84B | 29.23%6.68B | 33.45%1.85B | 28.70%1.67B | 23.05%1.6B | 31.65%1.57B | 19.11%5.17B | 19.93%1.38B |
Gross profit | 3.88%2.16B | 3.68%582.11M | 22.67%557.73M | 33.33%2.08B | 48.47%556.33M | 20.81%511.55M | 43.57%561.46M | 21.64%454.65M | 10.52%1.56B | 11.12%374.72M |
Operating expense | -0.39%979.51M | 2.58%233.03M | -2.92%209.22M | 12.74%983.29M | 22.15%259.82M | 9.34%280.8M | 13.62%227.17M | 6.30%215.51M | 4.61%872.18M | 10.94%212.7M |
Staff costs | -7.31%480.66M | ---- | ---- | 7.15%518.57M | ---- | ---- | ---- | ---- | 6.87%483.94M | ---- |
Selling and administrative expenses | 8.78%185.05M | ---- | ---- | 33.46%170.12M | ---- | ---- | ---- | ---- | 0.62%127.46M | ---- |
-General and administrative expense | 8.78%185.05M | ---- | ---- | 33.46%170.12M | ---- | ---- | ---- | ---- | 0.62%127.46M | ---- |
Depreciation and amortization | -1.62%93.8M | ---- | ---- | 348.06%95.34M | ---- | ---- | ---- | ---- | 4.11%21.28M | ---- |
-Depreciation | -3.76%39.65M | ---- | ---- | 93.59%41.2M | ---- | ---- | ---- | ---- | 4.11%21.28M | ---- |
-Amortization | 0.00%54.15M | ---- | ---- | --54.15M | ---- | ---- | ---- | ---- | ---- | ---- |
Rent and land expenses | 43.88%28.11M | ---- | ---- | -71.97%19.54M | ---- | ---- | ---- | ---- | -1.32%69.7M | ---- |
Other operating expenses | 6.77%191.89M | ---- | ---- | 5.85%179.73M | ---- | ---- | ---- | ---- | 4.03%169.8M | ---- |
Operating profit | 7.68%1.19B | 4.42%349.07M | 45.73%348.51M | 59.34%1.1B | 83.01%296.51M | 38.49%230.75M | 74.90%334.29M | 39.83%239.15M | 19.02%690.79M | 11.35%162.02M |
Net non-operating interest income (expenses) | 33.46%-521K | 11.11%-176K | 18.42%-186K | -67.67%-783K | -1,800.00%-170K | -152.70%-187K | 11.61%-198K | -27.37%-228K | 95.49%-467K | 100.55%10K |
Non-operating interest income | 578.57%190K | -10.00%9K | 0.00%4K | -6.67%28K | 0.00%10K | 0.00%4K | -16.67%10K | 0.00%4K | 25.00%30K | 11.11%10K |
Non-operating interest expense | -12.33%711K | -11.06%185K | -18.10%190K | --811K | --180K | --191K | --208K | --232K | ---- | ---- |
Total other finance cost | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -95.21%497K | --0 |
Net investment income | 22.32%11.39M | 49.72%9.31M | 148.58%4.03M | 17.33%3.26M | 79.27%6.22M | 20.81%1.62M | ||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 407K | 0 | 0 | 0 | 407K | ||
Income from associates and other participating interests | 0 | 0 | -3.72M | 2K | -377K | |||||
Special income (charges) | -42.57%-144K | -63.79%63K | 33.78%994K | -134.71%-101K | -1.02M | 0 | 174K | 743K | -70.99%291K | 0 |
Less:Other special charges | -64.79%144K | ---- | ---- | 240.55%409K | --1.02M | --0 | ---174K | ---435K | 70.99%-291K | --0 |
Less:Write off | --0 | --0 | -222.73%-994K | ---308K | --0 | --0 | --0 | ---308K | ---- | ---- |
Other non-operating income (expenses) | -52.63%12.35M | -5.14%10.02M | -37.98%374K | -6.87%26.06M | -81.07%120K | -12.22%14.78M | 4,010.89%10.57M | -94.12%603K | 255.05%27.99M | 190.83%634K |
Income before tax | 6.40%1.21B | 4.32%361.84M | 45.53%349.7M | 56.67%1.14B | 84.79%303.56M | 31.52%244.88M | 79.50%346.85M | 32.68%240.3M | 24.46%724.82M | 13.10%164.28M |
Income tax | 33.63%395.51M | -9.77%101.98M | 23.03%98.06M | 31.16%295.98M | -60.46%21.18M | 43.56%82.06M | 90.53%113.03M | 43.35%79.7M | 39.93%225.66M | 74.00%53.58M |
Net income | -3.19%812.79M | 11.13%259.86M | 56.69%251.64M | 68.21%839.61M | 155.09%282.38M | 26.18%162.81M | 74.61%233.83M | 27.95%160.59M | 18.53%499.15M | -3.28%110.7M |
Net income continuous operations | -3.19%812.79M | 11.13%259.86M | 56.69%251.64M | 68.21%839.61M | 155.09%282.37M | 26.18%162.82M | 74.61%233.83M | 27.95%160.59M | 18.53%499.15M | -3.28%110.7M |
Noncontrolling interests | 23.17%2.84M | -18.84%1.81M | 331.91%654K | 2.31M | 2.18M | -1.82M | 2.23M | -282K | ||
Net income attributable to the company | -3.27%809.95M | 11.42%258.05M | 56.01%250.98M | 67.74%837.3M | 153.12%280.19M | 27.59%164.64M | 72.95%231.6M | 28.18%160.88M | 18.53%499.15M | -3.28%110.7M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -3.27%809.95M | 11.42%258.05M | 56.01%250.98M | 67.74%837.3M | 153.12%280.19M | 27.59%164.64M | 72.95%231.6M | 28.18%160.88M | 18.53%499.15M | -3.28%110.7M |
Gross dividend payment | ||||||||||
Basic earnings per share | -0.80%21.15 | 15.77%6.79 | 61.15%6.575 | 71.04%21.32 | 156.18%7.205 | 28.01%4.17 | 77.46%5.865 | 32.04%4.08 | 6.90%12.465 | -5.38%2.8125 |
Diluted earnings per share | -0.75%21.15 | 14.26%6.7016 | 61.35%6.575 | 71.10%21.31 | 156.00%7.2 | 28.21%4.17 | 77.46%5.865 | 32.09%4.075 | 8.33%12.455 | -4.58%2.8125 |
Dividend per share | 33.33%9 | 0 | 0 | 35.00%6.75 | 35.00%6.75 | 0 | 0 | 0 | 11.11%5 | 11.11%5 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |